| Timetable |
| Download Conference Program |
| Download All Abstracts |
| Zoom Access |
| Corporate Program |
Poster Presentations
Day 4, June 25（Wed.）
Room P (Maesato East, Foyer, Ocean Wing)
- 4P-AM-31
Fundamental Study on Ionization Conditions for MALDI Mass Spectrometry Imaging of Novel Agents for Boron Neutron Capture Therapy.
(Univ. Osaka)
oRena Yamashita
Boron neutron capture therapy (BNCT) is an innovative cancer treatment that combines boron-containing agents, which selectively accumulate in cancer cells, with thermal neutron irradiation. The only boron agent currently used in insured medical treatment in Japan is BPA (boronophenylalanine). Its low accumulation in cancer cells remains a challenge, and the development and practical application of novel boron agents with higher accumulation selectively for tumors are expected for the advancement and spreading of BNCT. Molecular imaging is an essential method for the analysis of pharmacokinetics in drug development. Especially, mass spectrometry imaging (MSI) enables the simultaneous detection of multiple components and analyses in a short time at low cost, and it is a promising tool for novel drug development. In this study, BPA measurement and MSI using matrix-assisted laser desorption/ionization (MALDI) was conducted by changing the combination of the solvents and matrices to improve the sensitivity and reproducibility of MSI for BPA. Importance of sample solubility and fine, uniform crystallization of the sample were demonstrated.